Learn about the analytical performance and enhancements of next-generation sequencing-based liquid biopsy technology in this 52-minute webinar presented by experts Jennifer S. Lococo, Maria Jarama Ruiz, and Biswajit Das. Explore how the improved TruSight™ Oncology 500 ctDNA version 2 workflow reduces cfDNA input requirements and turnaround time while maintaining comprehensive genomic profiling capabilities for solid tumors. Gain insights into the assay's key features, analytical performance metrics, and real-world data from early access implementation. Discover how this emerging standard of care in oncology delivers crucial biomarker data through an optimized library preparation method designed for various biopsy types, including FFPE and cfDNA samples.
Analytical Performance of TruSight Oncology 500 ctDNA v2
Overview
Syllabus
Analytical performance of TruSight™ Oncology 500 ctDNA v2
Taught by
Labroots
Related Courses
-
Using Illumina TSO 500 ctDNA v2 Assay in Support of NCI Trial Research
-
Clinical Utility of NGS in Liquid Biopsy for Lung Cancer
-
Gaining Multi-dimensional Insights into Cancer Heterogeneity: Co-analysis of CTCs and ctDNA from Liquid Biopsy Samples
-
Rapid Tissue-Based Molecular Testing in Oncology - Clinical Utility of Amplicon-Based Comprehensive Testing
-
Early ctDNA Molecular Response Enhanced Through Integrated Analyses of Cell-Free DNA and Matched White Blood Cells
-
From 50 to 500 Genes: How to Scale to Comprehensive Genomic Profiling While Reducing Cost, Time and Labor
